IK-595 is a small molecule commercialized by Ikena Oncology, with a leading Phase I program in Thyroid Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of IK-595’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for IK-595 is expected to reach an annual total of $29 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
IK-595 Overview
IK-595 is under development for the treatment of solid tumor, pancreatic cancer, non-small cell lung cancer, colorectal cancer, melanoma, thyroid carcinoma, nerve sheath tumors, gliomas, breast cancer, acute myeloid leukemia model. It is administered through oral route. It acts by targeting mitogen activated protein kinase kinase (MEK)-RAF complex.
Ikena Oncology Overview
Ikena Oncology is a clinical-stage biotechnology company that discovers and develops novel cancer therapies. Its pipeline products include IK-930, IK-595 and IK-175. The company’s pipeline treats hippo-altered cancers, RAS (Rat Sarcoma) mutated cancers and bladder cancer. Ikena Oncology targeted program carries out in hippo and RAS (Rat Sarcoma) such as IK-930 TEAD inhibitor and IK-595: MEK-CRAF inhibition. Its immune signal targeting programs in tumor microenvironment modulation (TME) such as AHR inhibition and IK-175: AHR antagonist. The company’s program is built on robust translational research. Ikena Oncology is headquartered in Boston, Massachusetts, the US.
The company reported revenues of (US Dollars) US$9.2 million for the fiscal year ended December 2023 (FY2023), a decrease of 41.3% over FY2022. The operating loss of the company was US$75.4 million in FY2023, compared to an operating loss of US$70.9 million in FY2022. The net loss of the company was US$68.2 million in FY2023, compared to a net loss of US$68.8 million in FY2022.
For a complete picture of IK-595’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
